From the article: "Another major focus of the Section is the potential of pharmacogenetics to improve clinical care. There is now robust evidence that variations in drug-metabolizing enzymes (in particular CYP2C19 and CYP2D6) are associated with levels of several antidepressant and antipsychotic medications. However, the role of such variation in clinical response and overall tolerability needs to be explored in larger, more diverse studies across the world. Our Section is therefore proud to be participating in the PSY-PGx project, a global non-industry-sponsored study funded by the European Union Horizon 2020 initiative that will test the effectiveness of pharmacogenetic testing in a broad range of psychiatric disorders."